Why Gilead’s $5bn Tubulis deal could reshape its solid tumour pipeline strategy
Gilead’s Tubulis deal strengthens its ADC pipeline, but oncology execution, safety and clinical proof now decide the upside.
Is ENHERTU plus pertuzumab on track to redefine first-line treatment in HER2-positive metastatic breast cancer?
EMA begins review of ENHERTU plus pertuzumab for first-line HER2-positive metastatic breast cancer. Find out what this means for frontline therapy options.
What Rakuten Medical’s deal with LOTTE Biologics signals for photoimmunotherapy scale-up
Rakuten Medical taps LOTTE Biologics for global supply of its Alluminox cancer platform. Find out what this deal means for photoimmunotherapy’s future.
How Celltrion’s HER2–CD3 bispecific could compete in the T-cell engager arena
Celltrion is going all-in on oncology biologics with ADCs, msAbs, and U.S. biomanufacturing scale-up. Find out what this shift means for global competition.